Clay Siegall’s Cool Blog And His Pursuit Of Truth

March 25, 2017

Human beings, the creatures that you and I embody, have been on the planet for anywhere from 2 million to 6 million years. Neanderthals, one of our ancestors, came before us and died out sometime in the early parts of human existence on this planet. Here is the million-dollar question — did human beings and Neanderthals kiss?

That is the kind of question that Clay Siegall wants answered. He is a scientist that believes in science above all else. So when an article about vegetarian Neanderthals pops up on NPR, he is quick to repost it on his blog. In case you were wondering, Neanderthals and human beings did kiss and scientists have gleaned the evidence off of mummified skulls.

I have to say that Clay Siegall’s blog is one of the most interesting things I have ever read. There is a lot from NPR and the NFL. Apparently, he really loves three letter acronyms that start with the letter N. The articles that he displays on his blog range from stars melting into black holes, microbes being investigated in space and unrestricted NFL free agents signing with the new teams. If it is science or football, Clay Siegall has the answer for you.

But it is his pursuit of scientific truths in cancer research that really sets him apart. In the 1980s, he began his career as a scientific researcher for cancer at the National Institute Of Health. It is here that he began to understand cancer as an incredibly diverse disease. Each cancer is unique in its own way and must be treated as such.

This knowledge led him to cofound Seattle Genetics, the largest employer in the biotech industry of the Pacific Northwest. He now leads over 1000 employees in a quest for better treatments for cancer and other autoimmune diseases such as lupus. They endeavor to understand cancer on a cellular level and develop drugs that target each unique cancer cell. The goal is to give oncologists around the world more options when it comes to drugs and treatments in order to better suit each individual cancer patient.